Recent discoveries in cancer genetics of exocrine pancreatic neoplasia

Digestion

Volumn 59, Issue 5, 1998, Pages 493-501

  Hahn, Stephan A ^a   Schmiegel, Wolff H ^a,b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Genes; Oncogenes; Pancreatic carcinoma; Tumor suppressor genes

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

CANCER GENETICS; CARCINOGENESIS; CELL CYCLE; GENE DELETION; GENE LOCUS; HUMAN; ONCOGENE; ONCOGENE K RAS; PANCREAS CARCINOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; ONCOGENES; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 0031950026     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007526     Document Type: Review

References (78)

1. Boring CC, Squires TS, Tong T: Cancer statistics, 1994. CA Cancer J Clin 1994;44:7-26.
2. Warshaw AL, del Castillo CF: Pancreatic carcinoma. N Engl J Med 1992;326:455-465.
3. Weinberg RA: Oncogenes, antioncogenes, and the molecular basis of multistep carcinogenesis. Cancer Res 1989;49:3713-3721.
4. Almoguerra C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-554.
5. Yanagisawa A, Ohtake K, Ohashi K, Hori M, Kitagawa T, Sugano H, Kato Y: Frequent c-Kiras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 1993;53:953-956.
6. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE: Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-3573.
7. DiGuiseppe JA, Hruban RH, Offerhaus GJ, Clement MJ, van den Berg FM, Cameron JL, van Mansfeld AD: Detection of K-ras mutation in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol 1994;144:889-895.
8. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE: Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-1734.
9. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991;253:49-53.
10. Hahn SA, Seymour AB, Hoque ATMS, Schutte M, da Costa LT, Redston MS, Caldas C, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 1995; 55:4670-4675.
11. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, Ranzani GN: K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994;54: 1556-1560.
12. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa LT, Yeo CJ, Kern SE: p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-3033.
13. Kalthoff H, Schmiegel W, Roeder C, Rasche D, Schmidt A, Lauer G, Thiele HG, Honold G, Pantel K, Riethmiiller G: p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 1993;8:289-298.
14. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B: Identification of p53 as a sequence-specific DNA-binding protein. Science 1991;252:1708-1711.
15. O'Rourke RW, Miller CW, Kalo GJ, Simon KJ, Chen DL, Dang CV, Koeffler HP: A potential transcriptional activation element in the p53 protein. Oncogene 1990;5:1829-1832.
16. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC: Mutational hotspots in the p53 gene in hepatocellular carcinomas. Nature 1991;350:427-428.
17. Bressac B, Kew M, Wands J, Ozturk M: Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350:429-431.
18. Denissenko MF, Pao A, Tang M-S, Pfeifer GP: Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 1996;274:430-432.
19. Brash DE, Rudolf JA, Simon JA: A role for sunlight in skin cancer: UV induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991;88:10124-10128.
20. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-707.
21. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG: Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997;57:3126-3130.
22. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
23. Huang L, Goodrow TL, Zhang S-Y, Klein-Szanto AJP, Chang H, Ruggeri BA: Deletion and mutation analyses of the p16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinoma. Cancer Res 1996;56:1137-1141.
24. Spruck III CH, Gonzales-Zuluota M, Shibata A, et al: p16 gene in uncultured tumours. Nature 1994;370:183-184.
25. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parson R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-825.
26. Peters G: Stifled by inhibitions. Nature 1994; 371:204-205.
27. White E: p53, guardian of Rb. Nature 1994; 371:21-22.
28. Sherr CJ: Mammalian G1 cyclins. Cell 1993; 73:1059-1065.
29. Hunter T, Pines P: Cyclin and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994; 79:573-582.
30. Stein GH, Beeson M, Gordon L: Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts. Science 1990; 249:666-669.
31. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311.
32. 1 arrest and apoptosis. Cancer Res 1994;54:1169-1174.
33. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352:345-347.
34. INK4. Science 1995;267:249-251.
35. INK4 is restricted to the subset of lung cancer that retains wildtype RB. Oncogene 1994;9:3375-3378.
36. INK4 in human cancer. Proc Natl Acad Sci USA 1994; 91:11045-11049.
37. Seymour AB, Hruban RH, Redston M, Caldas C, Powell SM, Kinzler KW, Yee CJ, Kern SE: Allelotype of pancreatic adenocarcinoma. Cancer Res 1994;54:2761-2764.
38. Huang L, Lang D, Geradts J, Obara T, Klein-Szanto AJP, Lynch HT, Ruggeri BA: Molecular and immunochemical analyses of RB1 and Cyclin D1 in human ductal pancreatic carcinomas and cell lines. Mol Carcinog 1996;15:85-95.
39. Hahn SA, Schutte M, Hoque ATM, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271:350-353.
40. Hahn SA, Hoque ATM, Moskaluk CA, da Costa LT, Schutte M, Rozenblum E, Seymour AB, Weinstein CL, Yeo CJ, Hruban RH, Kern SE: Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 1996;56:490-494.
41. Moskaluk CA, Hruban RA, Schutte M, Lietman AS, Smyrk T, Fusaro L, Fusaro R, Lynch J, Yeo CJ, Jackson CE, Lynch HT, S.E. K: Genomic sequencing of DPC4 in the analysis of familial pancreatic carcinoma. Diag Mol Pathol 1997;6:85-90.
42. Schutte M, Hruban RH, Hedrick L, Cho KR, Molnar G, Weinstein G, Bova S, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero B, Meltzer PS, Hahn SA, Kern SE: DPC4 gene in various tumor types. Cancer Res 1996;56: 2527-2530.
43. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Willson JKV, Markowitz S, Hamilton SR, Kern SE, Kinzler KW, Vogelstein B: Evaluation of candidate tumor suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996;13: 342-346.
44. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui L-C, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL: MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996;86:543-552.
45. Hahn SA, Bartsch D, Schroers A, Galehdari H, Becker M, Ramaswamy A, Schwarte-Waldhoff I, Maschek H, Schmiegel W: Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res 1998; in press.
46. Sekelsky JJ, Newfeld SJ, Raftery LA, Chartoff EH, Gelbart WM: Genetic characterization and cloning of Mothers against dpp, a gene required for decapentaplegic function in Drosophila melonagaster. Genetics 1995;139: 1347-1358.
47. Heldin C-H, Miyazono K, ten Dijke P: TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390: 465-471.
48. Riggins GJ, Kinzler KW, Vogelstein B, Thiagalingam S: Frequency of Smad gene mutations in human cancer. Cancer Res 1997;57: 2578-2580.
49. Hata A, Lo RS, Wotton D, Lagna G, Massagué J: Mutations increasing autoinhibition inactivate tumor suppressors Smad2 and Smad4. Nature 1997;388:82-87.
50. Riggins GJ, Thiagalingam S, Rozenblum E, Weinstein CL, Kern SE, Hamilton SR, Willson JKV, Markowitz SD, Kinzler KW, Vogelstein B: Mad-related genes in the human. Nat Genet 1996;13:347-349.
51. Höhne MW, Halatsch ME, Kahl GF, Weinel RJ: Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma. Cancer Res 1992;52: 2616-2619.
52. Schutte M, da Costa LT, Hahn SA, Moskaluk C, Hoque ATMS, Rozenblum E, Weinstein CL, Bittner M, Melzer PS, Trent JM, Yeo CJ, Hruban RH, Kern SE: Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci USA 1995;92:5950-5954.
53. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, et al: Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-792.
54. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Peterson GM, Yeo CE, Jackson CE, Lynch HT, Hruban RH, Kern SE: Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-5364.
55. Teng DH, Bogden R, Mitchell J, Baumgard M, Bell R, Berry S, Davis T, Ha PC, Kehrer R, Jammulapati S, Chen Q, Offit K, Skolnick MH, Tavtigian SV, Jhanwar S, Swedlund B, Wong AK, Kamb A: Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nat Genet 1996;13:241-244.
56. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE: A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996;13:117-119.
57. Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R, Ghadirian P, Perret C, Moslehi R, Dion F, Faucher MC, Dole K, Karimi S, Foulkes W, Lounis H, Warner E, GOSS P, Anderson D, Larsson C, Narod SA, Futreal PA: Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 1996;13:120-122.
58. McKie AB, Filipe MI, Lemoine NR: Abnormalities affecting the APC and MCC tumour suppressor gene loci in chromosome 5q occur frequently in gastric cancer but not in pancreatic cancer. Int J Cancer 1993;55:598-603.
59. Horii A, Nakatsuru S, Miyoshi Y, Ichii S, Nagase H, Ando H, Yanagisawa A, Tsuchiya E, Kato Y, Nakamura Y: Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res 1992;52:6696-6698.
60. Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Järvinen H, Powell SM, Jen J, Hamilton SR, Petersen GM, Kinzler KW, Vogelstein B, de la Chapelle A: Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-816.
61. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996;87:159-170.
62. Han H-Y, Yanagisawa YK, Kato Y, J.-G. P, Nakamura Y: Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. Cancer Res 1993;53:5087-5089.
63. Lynch HT, Fitzsimmons ML, Smyrk TC, Lanspa SJ, Watson P, McClellan J, Lynch JF: Familial pancreatic cancer: Clinicopathologic study of 18 nuclear families. Am J Gastroenterol 1990;85:54-60.
64. INK4a mutations in familial pancreatic carcinoma. Hum Mutat 1998; in press.
65. INK4 mutations. N Engl J Med 1995;333:970-974.
66. Whelan AJ, Bartsch D, Goodfellow PJ: A familial syndrome of pancreatic carcinoma and melanoma with a mutation in the CDKN2 tumor suppressor gene. N Engl J Med 1995; 333:975-977.
67. Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelstein B: Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992;256:102-105.
68. Tada M, Omata M, Kawai S, Saisho H, Ohto M, Saiki RK, Sninsky JJ: Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993;53:2472-2474.
69. Watanabe H, Sawabu N, Ohta H, Satomura Y, Yamakawa O, Motoo Y, Okai T, Takahashi H, Wakabayashi T: Identification of K-ras oncogene mutations in the pure pancreatic juice of patients with ductal pancreatic cancer. Jpn J Cancer Res 1993;84:961-965.
70. Suzuki H, Yoshida S, Ichikawa Y, Yokato H, Mutoh H, Koyama A, Fukazawa M, Todoroki T, Fukao K, Uchida K, Miwa M: K-ras mutations in pancreatic secretions and aspirates from two patients without pancreatic cancer. J Natl Cancer Inst 1994;86:1547-1549.
71. Berthélemy P, Bouisson M, Escourrou JE, Vaysse NV, Rumeau JL, Pradayrol L: Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Ann Intern Med 1995;123:188-191.
72. Kondo H, Sugano K, Fukayama N, Kyogoku A, Nose H, Shimada K, Ohdura H, Fukuda H, Ohtsu A, Yoshida S, Shimosato Y: Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer 1994;73:1589-1594.
73. Brentnall TA, Chen R, Lee JG, Kimmey MB, Bronner MP, Haggitt RC, Kowdley KV, Hecker LM, Byrd DR: Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinoma and pancreatitis. Cancer Res 1995;55:4264-4267.
74. Brentnall TA, Chen R, Kimmey MB, Hecker LM, Kowdley KV, Bronner MP, Byrd DR: Ras mutations and microsatellite instability detected in ERCP-derived pancreatic juice from patients with pancreatic cancer (abstract). Gastroenterology 1995;108:A452.
75. Moskaluk CA, Hruban RH, Kern SE: p16 and K-ras mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997;57:2140-2143.
76. Hiyama E, Kodama T, Shinbara K, Iwao T, Itoh M, Hiyama K. Shay J, Matsuura Y, Yokoyama T: Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 1997;57:326-331.
77. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, Brown EL: Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotech 1996; 14:1675-1680.
78. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW: Serial analysis of gene expression. Science 1995;270:484-487.